Artemether-Lumefantrine Dosing for Uncomplicated Malaria
For adults and children >35 kg with uncomplicated malaria, administer artemether 20 mg/lumefantrine 120 mg as 4 tablets at hour 0,4 tablets at hour 8, then 4 tablets twice daily (at hours 36,48,60, and 72) for a total of 24 tablets over 72 hours (3 days). 1
Standard Dosing Regimen
The weight-based dosing for the standard 3-day (6-dose) regimen is:
- >35 kg (adults and older children):
- Day 1: 4 tablets at 0 hours, 4 tablets at 8 hours
- Day 2: 4 tablets at 36 hours, 4 tablets at 48 hours
- Day 3: 4 tablets at 60 hours, 4 tablets at 72 hours
- Total: 24 tablets over 72 hours 1
Each tablet contains artemether 20 mg + lumefantrine 120 mg 1
Critical Administration Requirements
Must be taken with a fatty meal or drink to ensure adequate lumefantrine absorption 1. This is non-negotiable as lumefantrine bioavailability is significantly enhanced by fat intake, and inadequate absorption is a major contributor to treatment failure.
Important Clinical Considerations
Emerging Resistance Concerns
Recent CDC data shows concerning trends of treatment failures, particularly late recrudescences occurring 1-8 weeks after standard AL treatment 2. Based on this:
- Extended 5-day (10-dose) regimen: The CDC now recommends a 5-day course for treating uncomplicated P. falciparum malaria in the United States due to increasing treatment failures with the standard 3-day regimen 2
- The pooled treatment failure risk for data collected in 2018 or later was 7% compared to 4% before 2018 2
- 85% of AL failures were late recrudescences, suggesting inadequate drug exposure rather than true artemisinin resistance 2
Safety Profile
- Well tolerated with rapid parasite clearance (median 41.5 hours) and fever clearance (median 36.8 hours) 3
- Most adverse events are mild-to-moderate and malaria-related rather than drug-related 3, 4
- QTc prolongation can occur—avoid in patients at risk of QTc prolongation or taking QTc-prolonging medications 1
- Safe in all trimesters of pregnancy per WHO and CDC guidelines 1, 5
Efficacy Data
The standard 6-dose regimen demonstrates:
- 28-day cure rates of 96-100% in clinical trials 6, 3
- PCR-corrected efficacy of 90-99% across African sites 7
- Superior to non-artemisinin combinations but may be inferior to mefloquine-artesunate in some settings 8
Common Pitfalls to Avoid
- Inadequate fat intake: Ensure patients consume fatty food/drink with each dose—this is the most common cause of subtherapeutic lumefantrine levels
- Vomiting within 1 hour: Repeat the dose if vomiting occurs within 1 hour of administration
- Incomplete dosing: The complicated 6-dose schedule over 3 days requires clear patient education and ideally supervised administration 1
- Geographic considerations: Consider extended regimens for infections acquired in Africa given emerging resistance patterns 2
Alternative Considerations
If AL fails or is contraindicated, second-line options include:
- Atovaquone-proguanil (also requires fatty meal)
- Dihydroartemisinin-piperaquine (preferred by some guidelines, taken fasting)
- Quinine plus doxycycline (7-day course, more side effects) 1